U.S. markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.19%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.38%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.19%)
     
  • BTC-USD

    19,276.99
    -13.12 (-0.07%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Rational Vaccines Announces a Clinical Trial to Determine Baseline Characteristics of Patients Diagnosed With Recurrent Symptomatic Herpes Simplex Type 2 (HSV-2) Virus

·3 min read

Study to be conducted at two leading research institutions in the U.K.

Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate

WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the launch of a clinical trial designed to determine the baseline characteristics of patients diagnosed with recurrent symptomatic herpes simplex virus type 2 (HSV-2). In addition to assessing the typical baseline characteristics of population, the purpose of this study is also to determine the acceptance of clinical trial procedures and understand the interest of the target patient population to participate in a therapeutic Phase 1/2 HSV-2 vaccine study.

Rational Vaccines logo (PRNewsfoto/Rational Vaccines)
Rational Vaccines logo (PRNewsfoto/Rational Vaccines)

The study, "A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease," will be led by Dr. Rajul Patel, consultant physician for genitourinary and HIV medicine at Southampton University Hospital, Southampton, England. The trial will be conducted at Southampton University Hospital, and at Chelsea and Westminster Hospital, London, England.

"Most people living with herpes are unaware they have the infection leading to unrecognized transmission and spread of the virus. Patients who develop symptomatic herpetic disease suffer not only from recurrent physical symptoms, but  may also suffer from social stigma and isolation because the infection is usually transmitted sexually," said Kerstin Westritschnig, M.D., chief medical officer of Rational Vaccines. "There is no cure for herpes. There are no approved vaccines or immunotherapies or sufficiently reliable diagnostics currently available1. Antiviral medications developed in the 1970s can help to reduce the severity and frequency of symptoms but cannot cure the infection."

"We look forward to initiating this clinical study as these findings will help inform the design of our Phase 1/2 clinical trial which will evaluate our lead vaccine candidate for HSV-2," added Dr. Westritschnig.

For More Information About This Clinical Trial  
Please visit:  
www.clinicaltrials.gov Identifier: NCT05500053
or click: HERE

About Herpes Simplex Virus (HSV)
The herpes simplex virus (HSV), commonly referred to as herpes, is categorized into two types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2). HSV-1 is the primary cause of oral herpes but can also cause genital herpes. HSV-2 is the primary cause of genital herpes. According to a 2020 report by the World Health Organization (WHO), herpes infects billions globally2 – about a half a billion people worldwide are living with genital herpes, and several billion have an oral herpes infection. Both HSV-1 and HSV-2 infections are lifelong.

While most herpes infections are asymptomatic, a significant number of people experience a range of symptoms that vary in frequency and severity. The most common symptoms for both types of herpes are painful blisters or ulcers. In addition, many patients experience debilitating neuralgia, skin splits, fissures, minor abrasions, erythema, fever, chills, and myalgias. Both viruses are most contagious during a symptomatic outbreak, but they can still be transmitted in the absence of symptoms. Strong evidence has emerged that HSV-1 is a major risk factor for Alzheimer's disease3.

About Rational Vaccines
Rational Vaccines is revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases with its rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates. Led by a team of world-renowned scientists, the Company is headquartered in Woburn, MA with locations in Miami, FL and Oxford, UK. For more information, please visit www.rationalvaccines.com.

1https:/www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus and Herpes - STI Treatment Guidelines (cdc.gov)

2WHO | First global and regional estimates of HIV infections attributable to HSV-2 infection

3https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075814/

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/rational-vaccines-announces-a-clinical-trial-to-determine-baseline-characteristics-of-patients-diagnosed-with-recurrent-symptomatic-herpes-simplex-type--2-hsv-2-virus-301605324.html

SOURCE Rational Vaccines